
|Videos|October 29, 2021
Dr. Swerdloff on testosterone capsule for hypogonadal men
Author(s)Urology Times staff
“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.
Advertisement
In this video, Ronald Swerdloff, MD, discusses the takeaways of the study, “Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men,” presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Swerdloff is a professor of medicine and senior investigator at The Lundquist Institute, Harbor-UCLA Medical Center and David Geffen School of Medicine, University of California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Testosterone deficiency: FAQs from the AUA guideline
2
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
3
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
4
From hype to practice: Urologists assess AI's real impact
5












